Our recent studies have confirmed that the TGF-β pathway acts as a potent tumour suppressor pathway in cSCC with mutational inactivation of TGFBR1 and/or TGFBR2 occurring in ~40% of cSCC tumours15. This evidence concerns the gene TGFB1 and skin squamous cell carcinoma.